MEDVi review: pricing, fine print, and how it ranks

The price, in words

On tirzepatide, MEDVi prices out at $399 a month all-in at the 10 mg maintenance basis, flat at every dose from 2.5 to 15 mg, no membership fee. Prepaid terms bring the effective rate to $249/mo (12-month plan). That ranks #14 of 17 priced compounded programs — $184 a month above the field's floor (NexLife at $215). Semaglutide runs $299 a month all-in at the standing rate ($179 on intro/plan terms). (#16 of 19 on our semaglutide basis)

What the fine print says

The $249/mo figure requires paying the 12-month plan up front; in a contested regulatory environment, read the refund terms before locking a year into any compounded program. Advertised as a 'starting at' price. Other formats and higher doses cost more, and the lowest figure is tied to a 12-month plan.

Pharmacy & transparency

Price evidence: Source-verified, last verified 2026-08-05. The dispensing pharmacy is not named publicly — the single most common transparency gap in this market. Ask which pharmacy fills the prescription, whether it is 503A or 503B, and whether a certificate of analysis is available; our pharmacy guide explains what each answer means.

The dose ladder, priced rung by rung

Walk MEDVi's ladder and the price never moves: every rung from 2.5 to 15 mg bills the same $399, which turns titration from a budgeting exercise into a clinical one. The practical consequences compound over a treatment course: the standard four-month climb to 10 mg costs exactly $1,596 (four flat months, no arithmetic), a post-plateau escalation from 10 to 12.5 mg is clinically free, and holding a dose an extra month for tolerability — the standard side-effect play — changes nothing on the bill. Against dose-scaled competitors whose entry figures climb 40–75% by maintenance, and against Zepbound's $299→$449 steps, a flat ladder means the advertised number is the number you keep paying.

What the first year actually bills

The annual number — the honest one — is $4,788 for year one on MEDVi's standing plan: twelve identical charges of $399, titration included, because the flat structure makes month one and month twelve the same line item. Prepay and the effective rate drops to $249/month (12-month plan), an annualized $2,988 — a real $1,800 saving against the standing year, purchased with locked funds whose refund terms deserve a read in a contested regulatory year. Benchmarked to the verified floor, the year costs $2,208 more than NexLife's $2,580 — the premium a buyer should be able to name a reason for. Brand context: Zepbound's comparable first year via LillyDirect runs about $5,188 on a standard titration, and $5,388 for a full year already at maintenance.

The 24-month view

Because this class works while taken, the two-year number deserves the spotlight: MEDVi at standing rates bills $9,576 across 24 months, against $5,976 if the prepaid rate could be held for both years ($3,600 of committed-money savings). The same 24 months cost $5,160 at the verified floor and $10,776 on brand Zepbound at maintenance — bookends worth writing on the first invoice.

The semaglutide side of the house

MEDVi prices semaglutide at $299/month all-in at the standing rate, ranking #16 of 19 on our verified semaglutide basis — against a field floor of $133 (Oak Longevity, with state limits) and brand Wegovy's flat $349. Plan detail worth reading before checkout: $299/mo refill rate, locked in; the first month is $179. A separate note in our semaglutide feed records CA/NC residents at $379.99 on the all-inclusive plan. The in-house premium for stepping up to tirzepatide is $100/month — the local price of SURMOUNT-5's 20.2%-vs-13.7% head-to-head result, and a switch that stays inside one program's intake and pharmacy relationships.

Where it sits in the market

On the verified tirzepatide board, MEDVi's $399 all-in rate ranks #14 of 17: $184/month above the NexLife floor; one rung cheaper sits Fridays at $359 (a $40/mo gap); one rung pricier is Remedy Meds at $399. Against the FDA-approved benchmark, the same year costs $600 less than Zepbound's $449 maintenance tier — the discount a buyer is accepting compounded-product risk to collect. The full board, sortable and dated, is the tirzepatide ranking.

Three buyers, priced honestly

The week-one starter. First month at the 2.5 mg rung: $399 — same as every later month on the flat plan. The 10 mg maintainer. Settled at maintenance, the run-rate is $399/month, $4,788/year — the figure that should anchor any comparison, since it describes years two and three, not the promo. The prepay optimizer. Committing to the 12-month plan cuts the effective rate to $249/month ($2,988/yr) — cheapest path here, least flexible money, refund terms first.

Nearest alternatives at this price point

Price-band neighbors worth a look before deciding: Remedy Meds at $399 (flat at every dose, no membership); Eden at $408 (source-verified); Fridays at $359 (flat at every dose, no membership, prepaid to $240) — each linked matchup runs the full head-to-head arithmetic on this exact question.

State availability

MEDVi publishes availability of: priced differently in CA/NC on some plans. California and North Carolina residents pay the $379.99 all-inclusive semaglutide rate here — one of the market's few genuine state surcharges. State-by-state context, exceptions, and city coverage live in the 51-state cost guides.

Five questions before checkout

Whatever the marketing says, get answers to: (1) the all-in monthly price at 10 mg and at 12.5 mg, in writing, including every mandatory fee; (2) which pharmacy, by name, fills the prescription — and whether it's 503A or 503B, licensed for your state, with a certificate of analysis available; (3) the refund terms on the prepaid plan, verbatim, before any multi-month charge; (4) the cancellation mechanics — deadline relative to renewal, written-confirmation availability, and whether any membership cancels separately. A program that answers all five plainly has already told you most of what this review can.

Visit MEDVi — verify current pricing →Opens the provider’s own pricing page; our figures were captured 2026-08-05.

Bottom line

MEDVi is one of the more expensive tirzepatide programs we track. For context, the verified market floor is $215/mo compounded tirzepatide and $133/mo compounded semaglutide, with brand Zepbound at $449/mo and Wegovy at $349/mo at maintenance.